B
KRYS icon

Braidwell’s Krystal Biotech KRYS Stock Holding History

Braidwell’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.1M Sell
182,425
-19,676
-10% -$5.24M 1.57% 20
2025
Q4 		$49.8M Sell
202,101
-318,300
-61% -$67M 1.59% 24
2025
Q3 		$91.9M Sell
520,401
-207,410
-28% -$31M 2.73% 8
2025
Q2 		$100M Buy
727,811
+327,067
+82% +$48M 3.42% 8
2025
Q1 		$72.3M Buy
400,744
+200,244
+100% +$33.7M 2.54% 13
2024
Q4 		$31.4M Buy
200,500
+31,809
+19% +$5.64M 0.93% 40
2024
Q3 		$30.7M Buy
168,691
+61,512
+57% +$11.9M 0.87% 42
2024
Q2 		$19.7M Sell
107,179
-69,910
-39% -$11.7M 0.62% 47
2024
Q1 		$31.5M Sell
177,089
-19,111
-10% -$2.65M 1.02% 38
2023
Q4 		$24.3M Buy
196,200
+118,703
+153% +$13.2M 0.89% 38
2023
Q3 		$8.99M Sell
77,497
-163,902
-68% -$20M 0.28% 80
2023
Q2 		$28.3M Sell
241,399
-106,637
-31% -$10.9M 0.93% 39
2023
Q1 		$27.9M Sell
348,036
-10,020
-3% -$787K 0.92% 43
2022
Q4 		$28.4M Buy
+358,056
New +$26.6M 0.95% 41

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Braidwell's KRYS Position: Q1 2026 in Review

Braidwell reduced its Krystal Biotech (KRYS) stake by 9.7% in Q1 2026, selling an estimated $5.24M and leaving 182,425 shares worth $47.1M. The position accounts for 1.57% of the portfolio, ranked #20.

Braidwell first reported a position in KRYS in Q4 2022 and has held it in 14 quarters since. The position peaked at $100M in Q2 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Braidwell held 182,425 shares of Krystal Biotech worth $47.1M as of Q1 2026.
  • Braidwell sold 19,676 Krystal Biotech shares in Q1 2026, an estimated $5.24M.
  • Krystal Biotech made up 1.57% of Braidwell's portfolio in Q1 2026, its #20 holding.
  • Braidwell first reported a position in Krystal Biotech in Q4 2022 and has held it in 14 quarters since.
  • Braidwell's Krystal Biotech position peaked at $100M in Q2 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.